FDA Head Touts Deeper Patient Input In Drugmaking Process

Law360, Washington (April 23, 2013, 8:25 PM EDT) -- A new push for deeper patient involvement in developing drugs, sparked in part by last year's user fee law, will have a significant impact on the drug development and approval process, the U.S. Food and Drug Administration commissioner said Tuesday.

FDA Commissioner Margaret Hamburg, speaking to a meeting of food and drug lawyers in Washington on Tuesday, announced a new website where patients can more directly interact with the FDA and sign up to be patient representatives on advisory committees and elsewhere in the approval process....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.